Philips Launches AI-Powered CT 5300 System at RSNA
The computed tomography device reportedly offers enhanced post-processing of images as well as bolstered image reconstruction capabilities with an 80 percent reduction in radiation dosing.
Combining enhanced imaging with significant reductions in patient positioning time and radiation dosing, Philips unveiled the artificial intelligence (AI)-enabled CT 5300 computed tomography (CT) system at the Radiological Society of North America (RSNA) conference.
Emphasizing precision software capabilities, the CT 5300 system includes CT Smart Workflow, which offers an array of AI-powered tools to drive workflow efficiencies, according to Philips.
The CT 5300 system includes CT Smart Workflow, which offers an array of AI-powered tools to facilitate significant workflow efficiencies, according to Philips, the manufacturer of the system. (Image courtesy of Philips.)
The company says key features of the CT 5300 device include:
• Precise Position, which facilitates up to a 23 percent reduction in patient positioning time;
• Precise Image, which enables rapid image reconstruction with an 80 percent reduction in radiation dosing; and
• the Advanced Visualization Workspace, which combines expedited reporting with a scalable, AI-powered post-processing platform for images.
(Editor’s note: For additional coverage from RSNA, click here.)
“By equipping the CT 5300 with our unique NanoPanel Precise detector and ultra-low noise Precise Image reconstruction technology, together with our latest AI-driven CT Smart Workflow solutions, we are integrating hardware, software, and AI to make high-quality care more productive, cost-effective, and widely accessible,” said Dan Xu, the CT business leader at Philips. “The productivity and diagnostic confidence enhancements that AI can deliver to CT imaging empower care teams and ease departmental workflow, helping to mitigate today’s chronic shortage of highly skilled radiologists and technicians.”
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
